Search Results
May 27, 2026, 07:00 ET BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.The Phase 2a expansion part of the trial is planned to include additional indications, including newly diagnosed GBM,
More news about: BioLineRx Ltd.
May 27, 2026, 05:38 ET Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
new, efficient treatment option for adult patients with NF1-PN.Furthermore, Henlius' HLX43, a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, will have its key subgroup progression-free survival (PFS) data in non-small cell lung cancer (NSCLC) presented for the first time in a Rapid
More news about: Fosun
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
Baseline biomarker analysis and clinical outcomes of the PD-1/TGFβR2 bispecific antibody INCA33890 in patients with non-MSI-H metastatic colorectal cancer (mCRC).
More news about: Hackensack Meridian John Theurer Cancer Center
May 26, 2026, 09:32 ET New Parkinson's Foundation PD Trial Navigator Program Identifies 2,000+ Potential Participants for NEULARK Clinical Trial
PD Trial Navigator pilot program. Aiming to advance the process of matching people living with PD with relevant studies, the PD Trial Navigator initiative identified more than 2,000 potential participants for screening
More news about: Parkinson's Foundation
May 26, 2026, 09:26 ET At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
Transplantation (HSCT) before or after being treated with a PD-1/PDL1 blocking antibody. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT.Embryo-Fetal
More news about: Sun Pharma
May 26, 2026, 08:40 ET Lion Delivers High-Grade Copper Intercepts and Positive Metallurgy on Low-Low Grade Mineralization
with all assay results expected by mid-June for adding to the initial NI-43-101 Mineral Resource Estimate (MRE) on Lion, and an update of the Nisk Ni-Cu-Pd deposit MRE with completion and reporting of estimates by the end of July. This MRE will form the basis for a Preliminary Economic Assessment (PEA) to
More news about: Power Metallic Mines Inc.
May 26, 2026, 08:39 ET Urban Poling Inc. and PWR! Partner Up at the World Parkinson's Conference to Support Mobility for the Parkinson's Community
pioneering innovative programs, and equipping professionals worldwide to better serve the PD community. They advocate for PD-specific skill training to sustain and retrain quality everyday movements that deteriorate in PD. These fundamental skills, the PWR!Moves, target multiple symptoms and can be integrated
More news about: Urban Poling Inc.
May 26, 2026, 08:30 ET Deepening Focus on Autoimmune Diseases, Empowering AI-Driven Drug Discovery
AI-discovered molecules improve clinical translation success rates.Integrated evaluation services include:Pharmacodynamics (PD)Pharmacokinetics (PK)Preliminary toxicologyMultiple endpoints can be evaluated within the same NHP model, enabling effective
More news about: HKeyBio
May 26, 2026, 08:00 ET Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) has been selected for poster presentation at the American Society of Clinical Oncology
More news about: Citius Oncology, Inc.
May 26, 2026, 07:30 ET Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcendo will sponsor the Phase 1b clinical trial and MSD
More news about: Adcendo
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab
More news about: Adcendo
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
presentations. The datasets featured at ASCO 2026 primarily highlight the Company's core first-in-class bispecific antibodies — cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) — along with other novel therapeutic antibodies such as ligufalimab, a next-generation CD47 monoclonal antibody. These presentations
More news about: Akeso, Inc.
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 211.Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC). (Abstract 1125) Session: Breast Cancer—Metastatic. Date/Time:
More news about: Caris Life Sciences
May 22, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Brings the Power of Its Integrated Network to ASCO 2026
RADIOHEAD pan-cancer cohort (Abstract 2533).CTX-8371 (Patrick Ott, MD, PhD — Dana-Farber): Phase 1 dose escalation of a novel PD-1 × PD-L1 bispecific antibody in patients with advanced malignancies post checkpoint inhibition (Abstract 2629).Axi-Cel Real-World Outcomes
More news about: Parker Institute for Cancer Immunotherapy
May 22, 2026, 07:00 ET BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during H2 2026, with full results on the dose escalation part expected in 2027.The
More news about: BioLineRx Ltd.; Hemispherian AS
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
negative or low PD‑L1 expression, the benefit from current immunotherapies is limited. In the Keynote‑407 study, in first‑line squamous NSCLC patients treated with PD‑1 combined with chemotherapy, the ORRs were 54.5% and 67.4% for the PD‑L1 1–49% and PD‑L1 <1% subgroups,
More news about: Innovent Biologics
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506)Efficacy and safety
More news about: Kelun-Biotech
May 21, 2026, 20:00 ET 2026 ASCO | 科倫博泰2項 註冊研究入選2026 ASCO非小細胞肺癌口頭報告專場
口頭報告：當地時間5月29日15:12-15:24 (摘要編號#8506，肺癌—轉移性非小細胞)研究共納入413例既往未接受系統治療的無表皮生長因數受體(EGFR)/間變性淋巴瘤激酶(ALK)突變且程式性細胞死亡配體1 (PD-L1)表達陽性(定義為腫瘤細胞陽性比例分數(TPS)≥1%)的局部晚期或轉移性NSCLC患者，覆蓋鱗狀和非鱗狀組織學類型，按1:1隨機分配接受蘆康沙妥珠單抗(sac-TMT) (4 mg/kg，Q2W)聯合帕博利珠單抗(400 mg，Q6W)或帕博利珠單抗單藥(400 mg, Q6W)治療。研究主要終點為經盲態獨立中心評估(BICR) 評估的無進展生存期(PFS)，關鍵次要終點為總生存期(OS)。截至2025年9月29日，中位隨訪時間為10.5個月。研究結果顯示：
More news about: 科倫博泰
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
survival benefits."About IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein)IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the
More news about: Innovent Biologics
May 21, 2026, 18:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On
More news about: Pomerantz LLP
May 21, 2026, 17:00 ET Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
the safety and tolerability of ATX-295 and determination of the RP2D. Secondary endpoints include assessment of pharmacokinetics (PK), pharmacodynamic (PD) effects, and preliminary antitumor activity. The Phase 1/2 study is currently open and actively enrolling patients.Details for the presentation
More news about: Accent Therapeutics
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
First-line (1L) olomorasib + pembrolizumab in patients with KRASG12C-mutant advanced NSCLC, and PD-L1expression 0-49%, from the doseoptimization cohorts of LOXO-RAS-20001and SUNRAY-01
More news about: Eli Lilly and Company
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
advanced disease. The enrolled population includes patients with programmed death ligand 1 (PD-L1)‑negative expression, as well as those with PD‑L1‑positive expression who have relapsed after prior anti-PD-(L)1 inhibitor in early stage disease. Two independent primary endpoints of the study are PFS and
More news about: Kelun-Biotech
May 21, 2026, 10:04 ET 第六項註冊臨床獲陽性結果！蘆康沙妥珠單抗(sac-TMT)對比化療一線治療晚期TNBC III期臨床達到PFS主要終點
(PD-L1)表達陰性患者，以及PD-L1表達陽性但既往在早期階段接受過PD-(L)1抑制劑治療後復發的患者。本研究以PFS和OS作為兩個獨立主要終點。在本次預設中期分析中，蘆康沙妥珠單抗(sac-TMT)在PFS方面顯示出顯著統計學意義和臨床意義的顯著改善；OS資料尚未成熟，目前觀察到積極獲益趨勢，將按方案繼續隨訪和在後續預設分析中進一步評估。安全性方面，蘆康沙妥珠單抗(sac-TMT)的安全性特徵與既往研究報告一致，未觀察到新的安全性信號。基於本研究結果，公司計畫就蘆康沙妥珠單抗(sac-TMT)用於
More news about: 科倫博泰